US Patent

US12251418 — Method of treating diseases

Method of Use · Assigned to Amryt Endo Inc · Expires 2036-02-03 · 10y remaining

Vulnerability score 75/100 Vulnerable — likely target for IPR or design-around

What this patent protects

Methods of treating acromegaly in a subject involve orally administering at least 20 mg of octreotide at least once daily, before or after a meal.

USPTO Abstract

Methods of treating acromegaly in a subject are described herein. Exemplary methods include orally administering to the subject at least once daily at least one dosage form comprising octreotide, wherein the octreotide in each dosage form is 20 mg, and wherein the administering occurs at least 1 hour before a meal or at least 2 hours after a meal.

Drugs covered by this patent

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

CodeDescriptionDrug
U-2857 octreotide-acetate

Patent Metadata

Patent number
US12251418
Jurisdiction
US
Classification
Method of Use
Expires
2036-02-03
Drug substance claim
No
Drug product claim
No
Assignee
Amryt Endo Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.